On the other hand, incretins, particularly glucagon-like peptide-1 (GLP-1), have emerged as important regulators of liver metabolism and are increasingly recognized for their role in MASLD pathophysiology and its progression to MASH. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.